New Delhi: While the Indian pharmaceutical industry registered sales of USD 36.7 Bn in 2017, the overall global market was USD 1.13 Trillion in 2017. Although it is expected to grow at a compound annual growth rate (CAGR) of 22.4 per cent to reach USD 55 billion by 2020, there still remains a major distance to travel before India can establish itself as an international pharma leader.
With the theme Pharma Vision 2030 aimed at establishing India as the global industry leader, the 70th edition of the Indian Pharmaceutical Congress (IPC) is set to see one of the largest congregation of pharmacists and pharmaceutical professionals discussing burning issues in the pharmaceutical industry, from December 21-23, 2018 at Amity University.
Organized by the Indian Pharmaceutical Congress Association, a federation of five professional pharmaceutical bodies, and hosted by the Indian Pharmacy Graduates’ Association, IPC 2018 will see industry captains and thought leaders to discuss the challenges and solutions in the road to achieve Pharma Vision 2030.
The 70th IPC will be inaugurated by the Vice-President of India, Mr Venkaiah Naidu, and presided by Dilip Shanghvi, President of 70th IPC and Managing Director of Sun Pharma.
The 70th IPC will have the Women Empowerment and Training and Placement Committees for the first time boosting women and student growth in the industry.
The event is expected to attract 6,000 delegates this year from all the sections of the pharma fraternity. The event will also have 125 national and international speakers debating various high issues related to the India.
A series of firsts amongst other highlights will rule the three-day mega pharma event.
The Vice-President of India for the first time will meet 50 CEOs of top 50 companies in the Indian Pharma Industry.
For the first time, a session has been kept on women empowerment and a Women Empowerment Committee has been constituted.
For the first time, rare disease and orphan drugs will discussed in IPC as well as in India, as the nation still stands unaware about unrecognized disease which are extremely hard to treat with known drugs.
The latest developments of Make in India, Entrepreneurship, and Skill-Development will be discussed in the various sessions pertaining to the pharma industry.
It is the largest ever congregation of minds from academia, regulatory, industry, student community will deliberate upon to gain more say in the world pharma space than what India enjoys today.
Areas like ePharmacy, biosimilars, APIs and many other topics will be deliberated upon during the sessions.
An open session has been kept where the regulator and industry will openly criticize each other, sharing various ideas without reservation.